Deals this week: AzurRx BioPharma, Innovent Biologics, Tosk

6th July 2018 (Last Updated July 6th, 2018 00:00)

AzurRx BioPharma plans to raise $50m through a public offering of securities.

AzurRx BioPharma plans to raise $50m through a public offering of securities.

The company intends to issue the securities periodically in any combination of common stock, preferred stock, debt securities, and warrants.

The proceeds from the offering are intended to be used towards research and development, preclinical programmes, working capital and other general corporate purposes.

Disclosure Law Group has been appointed as legal adviser to the company for the transaction.

Based in the US, AzurRx BioPharma is a development-stage biopharmaceutical company focused on the development of recombinant proteins for the treatment of gastrointestinal diseases.

Innovent Biologics has filed a registration for an initial public offering of shares in Hong Kong to raise funds.

Innovent simultaneously plans to raise funds through a venture financing round led by Capital Group Cos and other investors.

Based in China, Innovent Biologics is a developer and manufacturer of monoclonal antibodies.

Tosk has raised $0.75m in a venture financing round involving the issue of equity securities to 13 investors.

The current transaction brings the total funds raised by the company to $1.52m.

"Innovent Biologics has filed a registration for an initial public offering of shares in Hong Kong to raise funds."

Based in the US, Tosk is a biopharmaceutical company that discovers and develops novel drugs for the treatment of cancer.

Oramed Pharmaceuticals has signed agreements with healthcare-focused investors for the purchase of 2.8 million shares of its common stock and warrants priced at $6.25 each and related warrants through a registered direct offering to raise $18.1m.

Zysman, Aharoni, Gayer and Sullivan & Worcester has been appointed as legal adviser to the company for the offering.

The offering is expected to close in July 2018, subject to customary closing conditions.

The company plans to use the funds towards R&D activities, working capital and general corporate purposes.

Based in Israel, Oramed is a clinical-stage pharmaceutical company focused on the development of oral drug delivery technologies.

Mersana Therapeutics plans to raise $250m through a public offering of securities.

The company intends to issue the securities periodically in any combination of common stock, preferred stock, and warrants.

The funds raised from the offering are intended to be used towards clinical development, working capital and general corporate purposes.

Ropes & Gray has been appointed as legal adviser to the company for the transaction.

Based in the US, Mersana Therapeutics is a clinical-stage biopharmaceutical company that develops immune-conjugate therapies.